Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer

Julie E. Bauman, Ricklie Julian, Nabil F. Saba, Trisha M. Wise-Draper, Douglas R. Adkins, Paul O’brien, Mary Jo Fidler, Michael K. Gibson, Umamaheswar Duvvuri, Margo Heath-Chiozzi, Diego Alvarado, Richard Gedrich, Philip Golden, Roger B. Cohen

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science